Cell>Point Completes Second Phase Of Its Lung Cancer Imaging Trial

Cell>Point, a company providing diagnostic imaging solutions, announced that it has completed the second phase of its three part clinical trial of 99mTc-EC-G. The latter promises to be used as a SPECT/CT imaging agent for diagnosing non-small cell lung cancer (NSCLC). Cell>Point is producing 99mTc-EC-G as a diagnostic imaging agent for cancer and cardiovascular conditions.

http://www.healthimaginghub.com/component/content/article/2211-Digital%20Radiography/1518-cellgpoint-completes-second-phase-of-its-lung-cancer-imaging-trial.html